41198
document
A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva . PURPOSE To test the effect of valacyclovir alone and with aspirin on the asymptomatic shedding of HSV-1 DNA in tears and saliva of healthy individuals . METHOD . The subjects ( n = 45 ) were randomized into three groups without regard to age , sex , or race . Group 1 ( n = 14 ) received the placebo , group 2 ( n = 15 ) received a dose of 500 mg valacyclovir once daily , and group 3 ( n = 16 ) received a dose of 500 mg valacyclovir once daily and 350 mg aspirin twice daily for 30 days . Ocular and oral swabs were collected twice daily for 30 days . DNA was extracted from all swabs and HSV-1 DNA copy numbers were determined . Statistical analysis was performed to compare the DNA copy numbers of the three groups . RESULTS There was no significant difference in the HSV-1 DNA copy numbers in the tears or saliva among any of the three treatment groups . The mean copy numbers +/- SE of mean ( SEM ) of HSV-1 DNA in tears were 340 +/- 35 , 1074 +/- 320 , and 630 +/- 51 for groups 1 , 2 , and 3 , and in saliva were 238 +/- 35 , 963 +/- 462 , and 493 +/- 25 , respectively , for groups 1 , 2 , and 3 . CONCLUSIONS No correlation was found between HSV-1 shedding and valacyclovir and valacyclovir with aspirin treatment . The HSV-1 DNA copy number was not reduced by treatment with 500 mg of valacyclovir daily or with a combination of daily valacyclovir ( 500 mg ) plus twice-daily doses of aspirin ( 350 mg ) over 30 days .
41199
Intervention_Control
placebo-controlled
41200
Intervention_Pharmacological
valacyclovir alone
41201
Intervention_Pharmacological
aspirin
41202
Intervention_Pharmacological
valacyclovir alone
41203
Intervention_Pharmacological
aspirin
41204
Intervention_Control
placebo
41205
Intervention_Pharmacological
500 mg valacyclovir once daily
41206
Intervention_Pharmacological
500 mg valacyclovir once daily and 350 mg aspirin
41207
Intervention_Pharmacological
valacyclovir
41208
Intervention_Pharmacological
valacyclovir with aspirin
41209
Intervention_Pharmacological
valacyclovir
41210
Intervention_Pharmacological
valacyclovir
41211
Intervention_Pharmacological
aspirin
41212
Outcome_Physical
HSV-1 DNA copy numbers in the tears or saliva
41213
Outcome_Physical
mean copy numbers +/- SE of mean ( SEM ) of HSV-1 DNA
41214
Outcome_Physical
HSV-1 shedding
41215
Participant_Condition
healthy
41216
Participant_Sample-size
n = 45